Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.22.4
Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 765 $ 14,471 $ 39,050,260 $ (23,648,898) $ (1,893,897) $ 13,522,701
Beginning balance, shares at Dec. 31, 2020 764,618 14,471,403        
Sale of common stock – investors $ 1,500 3,253,500 3,255,000
Sale of common stock - investors, shares   1,500,000        
Issuance of common stock - note holders $ 304 422,368 422,672
Issuance of common stock - note holders, shares   303,483        
Issuance of common stock - consultants $ 1,394 2,034,941 2,036,335
Issuance of common stock - consultants, shares   1,394,272        
Issuance of common stock – employees $ 2,861 3,289,329 3,292,190
Issuance of common stock - employees, shares   2,861,227        
Issuance of common stock upon exercise of warrants $ 31,743 87,753,676 87,785,419
Issuane of common stock upon exercise of warrants, shares   31,742,986        
Offering costs -exercise of warrants (7,379,064) (7,379,064)
Issuance of common stock for acquisition $ 750 1,251,750 1,252,500
Issuance of common stock for acquisition, shares   750,000        
Share-based compensation 5,053,704 5,053,704
Conversion under notes payable $ 6,139 12,242,368 12,248,507
Conversions under notes payable, shares   6,139,252        
Exercise of warrant liabilities 89,654,047 89,654,047
Shares reserved for future issuance of common stock as consideration for the Emmersive asset acquisition 7,400,000 7,400,000
Conversion of preferred stock to common $ (765) $ 765
Conversion of preferred stock to common, shares (764,618) 764,619        
Net (loss) income (246,138,300) 50,577 (246,087,723)
Ending balance, value at Jun. 30, 2021 $ 59,927 244,026,879 (269,787,198) (1,843,320) (27,543,712)
Ending balance, shares at Jun. 30, 2021 59,927,242        
Beginning balance, value at Mar. 31, 2021 $ 765 $ 25,686 66,002,229 (86,118,452) (1,865,863) (21,955,635)
Beginning balance, shares at Mar. 31, 2021 764,618 25,685,981        
Issuance of common stock - note holders, shares   451,272        
Issuance of common stock - consultants $ 451 (451)
Issuance of common stock – employees $ 1,598 (1,598)
Issuance of common stock - employees, shares   1,598,355        
Issuance of common stock upon exercise of warrants $ 30,862 86,063,953 86,094,815
Issuane of common stock upon exercise of warrants, shares   30,862,188        
Share-based compensation 1,393,268 1,393,268
Conversion under notes payable $ 565 1,153,922 1,154,487
Conversions under notes payable, shares   564,827        
Exercise of warrant liabilities 89,394,620 89,394,620
Shares reserved for future issuance of common stock as consideration for the Emmersive asset acquisition 7,400,000 7,400,000
Conversion of preferred stock to common $ (765) $ 765
Conversion of preferred stock to common, shares (764,618) 764,619        
Net (loss) income (183,668,746) 22,543 (183,646,203)
Warrants exercised, net of offering costs (7,379,064) (7,379,064)
Ending balance, value at Jun. 30, 2021 $ 59,927 244,026,879 (269,787,198) (1,843,320) (27,543,712)
Ending balance, shares at Jun. 30, 2021 59,927,242        
Beginning balance, value at Dec. 31, 2021 $ 150,118 850,096,635 (736,821,840) 20,262,129 133,687,042
Beginning balance, shares at Dec. 31, 2021 150,118,024        
Issuance of common stock - note holders $ 1,000 2,189,000 2,190,000
Issuance of common stock - consultants $ 40 102,523 102,563
Issuane of common stock upon exercise of warrants, shares   1,000,000        
Share-based compensation 2,081,764 2,081,764
Conversions under notes payable, shares   40,000        
Exercise of warrant liabilities 227,949,858 227,949,858
Net (loss) income (227,019,793) (18,690,055) (245,709,849)
Warrants exercised, net of offering costs $ 81,983 100,954,855 101,036,838
Offering costs upon issuance of warrants, shares   81,982,969        
Write off of investments 927,875 927,875
Investment in Magnifi U (301,256) (301,256)
Common stock issued by Cryptyde, Inc. 12,001,000 12,001,000
Spin-off of Cryptyde, Inc. (11,936,218) 299,608 (11,636,610)
Ending balance, value at Jun. 30, 2022 $ 233,141 1,181,292,871 (963,776,852) 4,580,064 222,329,225
Ending balance, shares at Jun. 30, 2022 233,140,993        
Beginning balance, value at Mar. 31, 2022 $ 188,053 1,053,407,146 (1,109,769,797) 15,145,821 (41,028,777)
Beginning balance, shares at Mar. 31, 2022 188,052,593        
Issuance of common stock - note holders 10,000 10,000
Issuance of common stock - note holders, shares   40,000        
Issuance of common stock - consultants 102,563 102,563
Share-based compensation (102,563) 1,040,882 938,319
Exercise of warrant liabilities 127,920,814 127,920,814
Net (loss) income 145,928,164 (12,532,865) 133,395,298
Warrants exercised, net of offering costs $ 45,088 (45,088)
Offering costs upon issuance of warrants, shares   45,048,400        
Write off of investments 927,875 927,875
Investment in Magnifi U (301,256) (301,256)
Common stock issued by Cryptyde, Inc. 12,001,000 12,001,000
Spin-off of Cryptyde, Inc. (11,936,218) 299,608 (11,636,610)
Ending balance, value at Jun. 30, 2022 $ 233,141 $ 1,181,292,871 $ (963,776,852) $ 4,580,064 $ 222,329,225
Ending balance, shares at Jun. 30, 2022 233,140,993